Pharmacy News

Display News Filters

NICE makes new recommendation for type II diabetes

Friday 29th March 2019
The new option for those with type II diabetes could work out cheaper than current drugs being prescribed.
Latest Jobs

A new recommendation has been issued by the National Institute of Care and Health Excellence (NICE) for the treatment of type II diabetes.

Adults in the UK will now be offered Steglatro (ertugliflozin) on the NHS as a monotherapy or as part of a dual therapy programme alongside metformin.

The sodium-glucose cotransporter-2 (SGLT-2) inhibitor has a 20 per cent lower acquisition cost than other SGLT-2 inhibitors, making it an attractive option for many people with the disorder.

It works out at a once daily dose costing just £29.40 for 28 days' of treatment. In trials, scientists recorded noticeable changes in HbA1c from baseline to the 26th week.

Louise Houson, managing director of  MSD UK & Ireland, which makes the drug, told Pharma Times: “The decision by NICE shows MSD’s commitment to meeting the needs of a growing population of people with type II diabetes.

“We recognise the financial burden that an increasing number of people living with chronic conditions, such as type II diabetes, puts on resources and we continue to work closely with NICE and the NHS to increase access to new treatments which could improve the standard of care, while trying to lessen the economic pressures often associated with them.”

At present it’s estimated that 3.7 million people in the UK are living with diabetes, which equates to around seven per cent of the population.

This figure represents a doubling of the number diagnosed in the last 20 years, with inactivity and obesity among its causes.

It is thought that on top of those who have been diagnosed with type II diabetes, there are around 12.3 million people at an increased risk of developing the condition.

Written by James Puckle

Search Mediplacements for the latest pharmacy jobs.ADNFCR-1780-ID-801849978-ADNFCR

Related News